nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

25.10.2016 | Letter to the Editor

Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma

verfasst von: Hugo J. A. Adams, Thomas C. Kwee

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Excerpt

Dear Sir, …

Fallanca F, Alongi P, Incerti E, Gianolli L, Picchio M, Kayani I, et al. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville criteria (DC) and the international harmonization project criteria (IHPC). Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3390-9.CrossRefPubMed

An YS, Yoon JK, Lee SJ, Jeong SH, Lee HW. Clinical significance of post-treatment F-fluorodeoxyglucose uptake in cervical lymph nodes in patients with diffuse large B-cell lymphoma. Eur Radiol. 2016. doi:10.1007/s00330-016-4365-8.CrossRefPubMed

Avivi I, Zilberlicht A, Dann EJ, Leiba R, Faibish T, Rowe JM, et al. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol. 2013;88:400–5. doi:10.1002/ajh.23423.CrossRefPubMed

Zinzani PL, Tani M, Trisolini R, Fanti S, Stefoni V, Alifano M, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica. 2007;92:771–7.CrossRefPubMed

Nakayama H, Aisa Y, Ito C, Shimazaki K, Katsumata Y, Hayashi H, et al. Importance of histologic verification of positive positron emission tomography/computed tomography findings in the follow-up of patients with malignant lymphoma. Clin Lymphoma Myeloma Leuk. 2015;15:753–60. doi:10.1016/j.clml.2015.07.636.CrossRefPubMed

Adams HJ, Nievelstein RA, Kwee TC. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. Br J Haematol. 2015;170:185–91. doi:10.1111/bjh.13420.CrossRefPubMed

Adams HJ, Kwee TC. Both interim and end-of-treatment 18F-fluoro-2-deoxy-d-glucose positron emission tomography scans have low value in diffuse large B-cell lymphoma. J Clin Oncol. 2016;34:765–6. doi:10.1200/JCO.2015.63.7728.CrossRefPubMed

Adams HJ, Kwee TC. Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Br J Haematol. 2016. doi:10.1111/bjh.14052.CrossRefPubMed

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced international prognostic index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42. doi:10.1182/blood-2013-09-524108.CrossRefPubMedPubMedCentral

10.

Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med. 1998;339:1506–14. doi:10.1056/NEJM199811193392104.CrossRefPubMed

11.

Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65. doi:10.1182/blood-2003-12-4434.CrossRefPubMed

Titel: Critical considerations on the predictive value of end-of-treatment FDG-PET in lymphoma
verfasst von: Hugo J. A. Adams
Thomas C. Kwee
Publikationsdatum: 25.10.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3553-8

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Clinical values of left ventricular mechanical dyssynchrony assessment by gated myocardial perfusion SPECT in patients with acute myocardial infarction and multivessel disease

Predictive medicine: towards a multi-parametric imaging for a personal risk stratification

Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer

Preclinical in vivo and in vitro comparison of the translocator protein PET ligands [18F]PBR102 and [18F]PBR111

Do we need FDG-PET/CT to assess atherosclerosis?

Brain perfusion SPECT for brain death assessment